Jennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Jennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32ndAnnual Meeting.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More